Janus Henderson's Stock Ratings

TD Cowen Analyst

Janus Henderson is an analyst at TD Cowen. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/09/2024

Overall Average Return

-%

Smart Score

1.91%

Overall Average Return Percentile

-

Number of Ratings

3
Buy NowGet Alert
07/08/2024JHGBuy Now
Janus Henderson Group
$34.779.29%$37 → $38MaintainsBuyGet Alert
05/15/2024JHGBuy Now
Janus Henderson Group
$34.776.41% → $37UpgradeHold → BuyGet Alert
04/06/2023JHGBuy Now
Janus Henderson Group
$34.77-27.24%$24.6 → $25.3UpgradeSell → NeutralGet Alert

Recent Analyst Stock Rating News

What 6 Analyst Ratings Have To Say About Janus Henderson Group
Analyzing KKR In Comparison To Competitors In Capital Markets Industry
UFP Technologies Makes A Healthy Move With AJR Buyout
UFP Technologies acquires AJR Enterprises for $110 million, expanding their capabilities and positioning them for growth in the safe patient handling market.
5 Growth Stocks to Buy for an Imposing Election Year Rally
The year 2023 was impressive for Wall Street. Heading into 2024, some bottlenecks, including geopolitical upheavals and stretched valuations, raised doubts about whether the rally will endure. However, major bourses shrugged off all these apprehensions and notched record highs.
Best Income Stocks to Buy for June 5th
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 5th: Janus Henderson Group plc (NYSE: JHG): This asset management company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.8% over the last 60 days.
3 Large-Cap Growth Funds to Buy as Inflation Cools in April
Inflation has been a major concern lately as uncertainty has been growing over the Federal Reserve's timing of rate cuts. However, much to consumers' relief, inflation finally eased in April after moving north in the first months of the year.
BHP Shareholders Anticipate Final Bid For Anglo American As Deadline Nears
Investors anticipate final bid from BHP for Anglo American, as May 22 deadline approaches.
Unveiling 7 Analyst Insights On Janus Henderson Group
Assessing KKR's Performance Against Competitors In Capital Markets Industry
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free